🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 20 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
12/11/2020 22,73 23,39 22,00 22,60 -1,22% 6,12% 297.300
11/11/2020 22,97 23,19 22,06 22,88 +1,02% 4,92% 334.100
10/11/2020 21,51 22,75 21,38 22,65 +5,20% 6,37% 456.400
09/11/2020 20,62 22,16 19,86 21,53 +6,22% 11,15% 581.900
06/11/2020 21,09 21,72 19,83 20,27 -3,11% 8,96% 448.800
05/11/2020 21,97 22,23 19,70 20,92 -4,17% 11,52% 1.147.500
04/11/2020 20,51 23,29 20,51 21,83 +5,05% 13,53% 1.028.900
03/11/2020 21,13 21,49 19,48 20,78 -1,19% 9,51% 1.037.100
02/11/2020 21,84 21,91 20,47 21,03 -3,53% 6,59% 888.300
30/10/2020 23,03 23,12 21,32 21,80 -6,92% 7,82% 946.300
29/10/2020 20,48 23,84 20,40 23,42 +14,24% 16,80% 1.107.800
28/10/2020 20,26 21,08 19,55 20,50 -1,11% 7,55% 503.700
27/10/2020 19,73 20,99 19,55 20,73 +4,49% 7,30% 623.500
26/10/2020 19,83 20,51 19,33 19,84 -1,49% 5,95% 410.100
23/10/2020 20,51 20,57 19,72 20,14 -0,93% 4,14% 452.100
22/10/2020 19,67 20,50 19,53 20,33 +4,26% 4,93% 572.400
21/10/2020 19,40 19,72 19,01 19,50 +0,83% 3,66% 498.400
20/10/2020 19,36 19,49 18,51 19,34 +0,05% 5,06% 770.200
19/10/2020 21,15 21,15 19,09 19,33 -8,00% 9,74% 830.700
16/10/2020 20,31 21,09 20,26 21,01 +3,45% 4,10% 229.700
15/10/2020 19,17 20,41 19,07 20,31 +3,78% 6,99% 276.400
14/10/2020 20,22 20,72 19,50 19,57 -3,74% 6,03% 348.200
13/10/2020 19,30 20,47 19,30 20,33 +4,10% 6,06% 340.400
12/10/2020 19,66 19,92 19,17 19,53 -0,51% 3,81% 258.300
09/10/2020 19,34 19,67 18,94 19,63 +2,24% 3,77% 216.100
08/10/2020 19,31 19,67 18,88 19,20 +0,79% 4,09% 435.100
07/10/2020 18,10 19,14 17,85 19,05 +6,72% 7,13% 380.700
06/10/2020 18,58 18,76 17,82 17,85 -3,98% 5,08% 432.700
05/10/2020 17,17 18,61 17,17 18,59 +9,35% 8,39% 384.100
02/10/2020 16,72 17,64 16,69 17,00 -0,99% 5,68% 435.700